NICE Recommends Ibrutinib for Relapsed/Refractory MCL

December 15, 2017 – The United Kingdom’s National Institute for Health Care and Excellence (NICE) has published new guidelines recommending ibrutinib as treatment for patients with relapsed/refractory mantle cell lymphoma (MCL). The BTK inhibitor is approved for patients who have undergone 1 previous line of therapy, and if Janssen Biotech, the drug’s manufacturer, provides ibrutinib “with the discount agreed in the commercial access agreement with NHS … (leggi tutto)